Elo Mutual Pension Insurance Co Reduces Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Elo Mutual Pension Insurance Co reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 113,615 shares of the biopharmaceutical company’s stock after selling 4,789 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Gilead Sciences were worth $10,495,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Southland Equity Partners LLC grew its holdings in shares of Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 110 shares during the last quarter. Berkshire Bank grew its stake in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 111 shares in the last quarter. CFO4Life Group LLC increased its position in shares of Gilead Sciences by 2.7% during the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock worth $394,000 after acquiring an additional 112 shares during the period. GHP Investment Advisors Inc. raised its stake in shares of Gilead Sciences by 1.1% during the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock valued at $1,049,000 after acquiring an additional 122 shares in the last quarter. Finally, J.W. Cole Advisors Inc. grew its stake in Gilead Sciences by 1.0% in the fourth quarter. J.W. Cole Advisors Inc. now owns 13,597 shares of the biopharmaceutical company’s stock worth $1,256,000 after purchasing an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

GILD opened at $109.27 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The firm has a 50 day moving average of $104.69 and a two-hundred day moving average of $94.46. The firm has a market capitalization of $136.08 billion, a PE ratio of 295.32, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a $0.79 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.89%. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Analyst Ratings Changes

Several equities research analysts have weighed in on GILD shares. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.